Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — UBS Global Healthcare Conference 2018
19 slides from Amneal Pharmaceuticals's conference presentation, May 21, 2018
Slide 1: Focused on Growth & Execution
“We make healthy possible” UBS Global Healthcare Conference Focused on Rob Stewart Growth & President and CEO Execution May 21, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as a
Slide 3: A Strong Foundation to Deliver Long-Term Growth
A Strong Foundation to Deliver Long-Term Growth GENERIC PRODUCT SPECIALTY PRODUCTS OUR PORTFOLIO FOCUS R&D CENTERS GLOBAL MANUFACTURING FAMILIES FACILITIES 200+ 6 Generics 811 GENERICS PIPELINE SPECIALTY PIPELINE Specialty 147 135 IPX203 ANNUAL R&D MANUFACTURING Products Under (Parkinson’s disease)
Slide 4: Combination Fuels Long-Term Growth
Combination Fuels Long-Term Growth * Estimated Adjusted EBITDA ($billions) z Annual double-digit revenue, adjusted EBITDA and adjusted EPS growth over next 3 years ~$1.1 z $200+ million in expected annual synergies within 3 years ~$0.60-$0.65 z Significant projected cash flow generation enables de-l
Slide 5: Diversified Generic Products Commercial Portfolio
Diversified Generic Products Commercial Portfolio Our portfolio consists of more than 200 product families including difficult-to-manufacture and high barrier-to-entry products across multiple dosage forms Yuvafem Adrenaclick Diclofenac Aspirin and Oseltamivir (Estradiol Vaginal (epinephrine Sodium
Slide 6: Stable Cash Flow from Specialty Franchise
Stable Cash Flow from Specialty Franchise z Proprietary marketed products í Central nervous system disorders í Parasitic infections í Other therapeutic areas z Established U.S. sales and marketing function 130 sales reps Primarily targeting neurologists, movement disorder specialists and other h
Slide 7: Broad R&D and Manufacturing Capabilities
Broad R&D and Manufacturing Capabilities Manufacturing and R&D Piscataway, NJ: API Complex and High Value Products, Distribution Topicals, Transdermals, High Potency and Hormonal Products Cashel, Ireland: Branchburg, NJ: MDI, DPI, Hormonal Injectables Oral Liquid Products, Nasal Sprays Dahej, India:
Slide 8: Diversified and High-Value Generic Pipeline
Diversified and High-Value Generic Pipeline Approximately 282 total projects of which ~50% are high value opportunities1 Transdermal Transdermal 5% - $2.4B Ophthalmic Nasal Spray 4% - $3.5B Other Nasal Spray 2% $0.3B 1% - $0.5B 1% - $0.1B 1% - $0.2B Inhalation Injectable 6% - $13.1B Topical 17% - $8
Slide 9: Pending ANDA Pipeline Offers Numerous Potential High-Value Opportunities to Drive Growth
Pending ANDA Pipeline Offers Numerous Potential High-Value Opportunities to Drive Growth A snapshot of only a few of the many high-value opportunities in our pipeline Products Brand LTM IMS Sales ® Dimethyl Fumarate DR Capsules Tecfidera $3,548 Glatiramer Injection 40mg Copaxone HD® $3,457 Lisdexamf
Slide 10: Ongoing Commitment to Invest in Biosimilar Pipeline
Ongoing Commitment to Invest in Biosimilar Pipeline New Partnership Existing Partnership z Amneal entered into a licensing and supply agreement for biosimilar candidate Avastin® (bevacizumab) z Amneal will be the exclusive partner for the bevacizumab Product Filed product in the US market z Amneal w
Slide 11: Streamlining Operations and Capturing Cost Synergies
Streamlining Operations and Capturing Cost Synergies z Phasing out Impax Hayward campus including manufacturing, R&D and other operations z Transferring products to Amneal’s lower-cost facilities in the U.S. and India z Anticipated completion timeline of ~12 to 15 months (completed by August 2019) z
Slide 12: Substantial Synergy Opportunity Expected
Substantial Synergy Opportunity Expected $200+ million in annual incremental synergies within 3 years of close1 Estimated Actual Cost Savings Realized by Year ($ in millions) $200+ $50+ $40-$45 $65-$70 $30-$35 2018E 2019E 2020E 2021E Total 2 ($ in millions) Previously Disclosed Run-Rate Synergies Sy
Slide 13: 2018 Key Guidance Assumptions
2018 Key Guidance Assumptions z Growth in adjusted EBITDA weighted towards second half of 2018 due to estimated timing of new approvals and launches z Generic division growth driven by new product launches which are expected to more than offset additional competition on existing portfolio Potentia
Slide 14: Full Year 2018 Financial Guidance
Full Year 2018 Financial Guidance Guidance Range Full Year 2018 Adjusted Gross Margins 50% - 55% Adjusted R&D Expense as a % of Total Revenues1 10% - 15% Adjusted SG&A Expense as a % of Total Revenues 13% - 16% Adjusted EBITDA2 $600 to $650 million Adjusted EPS $0.95 - $1.10 Adjusted Effective Tax R
Slide 15: Adjusted EBITDA Bridge to Full Year 2018 Guidance
Adjusted EBITDA Bridge to Full Year 2018 Guidance Recent Generic Approvals and Launches Demonstrate Significant Progress Towards 2018 Guidance Colesevelam (gWelchol), Vigabatrin POS and Phytonadione Adjusted EBITDA Year $625 Guidance To Go $600 to $650 Million $ millions $465 $381 +84.0 1Q 2018 Seas
Slide 16: Focused on Operational Execution…
Focused on Operational Execution… z Rapidly and seamlessly combine Amneal and Impax z Focus on synergy capture and cost control z Maintain high level of quality and compliance z Continue to provide superior service to our customers z Maximize value of enhanced commercial portfolio to grow revenue an
Slide 17: …And Continued Investment in Growth Initiatives
…And Continued Investment in Growth Initiatives OUR PORTFOLIO FOCUS Specialty Generics Biosimilars Products z Invest in organic growth through focused R&D z Pursue creative business development to strengthen our franchises and other adjacencies 17
Slide 18: Appendix
Appendix 18
Slide 19: Disclosed ANDA Pending Pipeline
Disclosed ANDA Pending Pipeline Product Brand LTM IMS Sales Product Brand LTM IMS Sales Pemetrexed injection Alimta® $1,053 Pitavastatin Calcium Tablet Livalo® $292 Lubiprostone Capsule Amitiza® $489 Guaifenesin Tablet Mucinex® $75 Testosterone Gel 1.62% Androgel® $1,062 Guaifenesin + Dextromethorph
Amneal Pharmaceuticals — UBS Global Healthcare Conference 2018 on 6ix